SAR443579
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for SAR443579, covering 2025-08-22 to 2026-07-06. Get the full timeline:
Most recent: Clinical Trial Results: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1, Phase 2]